Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Regeneron (REGN)
NASDAQ:REGN
Holding REGN?
Track your performance easily
Earnings Data
Report Date
Feb 04, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
11.25Last Year’s EPS
11.86Same Quarter Last Year
Moderate Buy
Based on 21 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 06, 2018
|% Change Since: -24.88%
|Next Earnings Date:Aug 02, 2018
Earnings Call Sentiment|Positive
The earnings call reflects a generally positive outlook driven by strong revenue growth and successful product performances, particularly Dupixent and EYLEA HD. However, there are challenges due to market competition and pricing pressures. Overall, the sentiment is cautiously optimistic, with significant growth opportunities anticipated in 2025.Company Guidance
During the Regeneron Pharmaceuticals Q3 2024 earnings call, several key financial metrics and strategic insights were provided. The company reported an 11% increase in total revenues to $3.72 billion, primarily due to a 24% revenue growth for DUPIXENT, which achieved global sales of $3.8 billion, and a 3% increase in combined net sales for EYLEA HD and EYLEA. The Sanofi collaboration contributed $1.3 billion to the total revenue, with a significant increase in collaboration profitability. EYLEA maintained a 44% market share in the anti-VEGF category, while Libtayo revenues grew by 24% year-over-year. Regeneron's R&D expenses rose to $1.1 billion, reflecting ongoing investments in their pipeline, which includes approximately 40 clinical programs. The company's net income per share for the quarter was $12.46, marking an 8% increase from the previous year, and they ended the quarter with $15.6 billion in net cash.Revenue Growth
Total revenues grew 11% to $3.72 billion, driven by higher Sanofi collaboration revenues and strong performance of Dupixent, Libtayo, and EYLEA.
Dupixent Success
Global revenues for Dupixent increased 24% on a constant currency basis to $3.8 billion, with over 1 million patients on treatment worldwide.
EYLEA HD Performance
EYLEA HD net sales grew 29% sequentially to $392 million, reflecting strong adoption and achieving billion-dollar brand status within the first year of launch.
Libtayo Growth
Global net sales of Libtayo increased 24% year-over-year to $289 million, with continued market share gains in lung cancer.
Pipeline Progress
Regeneron expects several upcoming readouts and regulatory filings in 2025, including pivotal data for fianlimab-libtayo combination in melanoma and Factor XI antibodies in thrombosis.
---
REGN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
REGN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Oct 31, 2024 | $922.79 | $838.20 | -9.17% |
| Aug 01, 2024 | $1079.19 | $1093.14 | +1.29% |
| May 02, 2024 | $903.48 | $937.61 | +3.78% |
| Feb 02, 2024 | $957.78 | $945.18 | -1.32% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Regeneron (REGN) report earnings?
Regeneron (REGN) is schdueled to report earning on Feb 04, 2025, TBA Not Confirmed.
What is Regeneron (REGN) earnings time?
Regeneron (REGN) earnings time is at Feb 04, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is REGN EPS forecast?
REGN EPS forecast for the fiscal quarter 2024 (Q4) is 11.25.
---
